首页 > 资讯 > 适应变化：循环杂志的新焦点综述探讨了减肥与肌肉健康之间的关系

适应变化：循环杂志的新焦点综述探讨了减肥与肌肉健康之间的关系

泰然健康网
2024-12-02 22:11

LINKÖPING, Sweden--(BUSINESS WIRE)--A focused review titled “Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?” was recently published in the renowned cardiovascular scientific journal, Circulation. Authored by AMRA Medical’s Dr. Jennifer Linge, professor Andreas Birkenfeld of University Hospital Tübingen, and associate professor Ian Neeland of University Hospitals Cleveland, the article discusses several aspects of the response associated with weight loss with respect to muscle health..

瑞典林克平——（商业新闻短讯）——一篇题为“肌肉质量和胰高血糖素样肽-1受体激动剂：对减肥的适应性或不适应性反应”的重点评论最近发表在著名的心血管科学杂志《循环》上。这篇文章由AMRA Medical的Jennifer Linge博士、蒂宾根大学医院的Andreas Birkenfeld教授和克利夫兰大学医院的Ian Neeland副教授撰写，讨论了与肌肉健康相关的减肥反应的几个方面。。

As pharmaceutical treatments, such as GLP-1 agonists, are reaching weight reductions of magnitudes close to those achieved through bariatric surgery, the concerns regarding a possible adverse impact on muscle health are growing. In light of this, the experts aimed to address whether muscle-related changes associated with weight loss treatments such as GLP-1 receptor agonists may be maladaptive (i.e., adversely impacting muscle health/function), adaptive (i.e., a physiologic response to weight loss maintaining or minimally affecting muscle health/function), or perhaps an enhanced response to weight loss (i.e., improved muscle health/function following treatment)..

随着药物治疗（如GLP-1激动剂）的体重减轻程度接近减肥手术所达到的程度，人们越来越担心可能对肌肉健康产生不利影响。有鉴于此，专家们旨在解决与减肥治疗相关的肌肉相关变化（如GLP-1受体激动剂）是否可能是适应不良（即对肌肉健康/功能产生不利影响），适应性（即对减肥的生理反应维持或对肌肉健康/功能的影响最小），或者可能是对减肥的增强反应（即治疗后肌肉健康/功能的改善）。。

Historical studies of GLP-1-based therapies and body composition have reported absolute and/or relative changes in total body lean mass. Results vary greatly from study to study, likely due to, e.g., variations in population characteristics, study durations, and dosing, but also because of the individual heterogeneity in lean mass composition - comprising not only muscle mass, but also organs, bone, fluids, and water in fat tissue..

基于GLP-1的疗法和身体成分的历史研究报告了全身瘦体重的绝对和/或相对变化。不同研究的结果差异很大，可能是由于人群特征，研究持续时间和剂量的变化，也可能是由于瘦体重组成的个体异质性-不仅包括肌肉质量，还包括脂肪组织中的器官，骨骼，液体和水。。

The heterogeneity in past study results makes it difficult for clinicians and researchers to determine what is “normal” or “healthy” weight reduction. However, recent studies in this area have utilized gold-standard MRI-based technology and muscle composition assessments including muscle volume (both in liters and as a sex-, height-, weight-, and BMI invariant z-score describing ‘relative or adequate muscle mass’) as well as muscle fat infiltration, providing muscle-specific data on the effect of incretin-based treatments.

。然而，最近在这一领域的研究利用了金标准的基于MRI的技术和肌肉组成评估，包括肌肉体积（以升为单位，以及描述“相对或足够肌肉质量”的性别，身高，体重和BMI不变z评分）以及肌肉脂肪浸润，提供了关于肠降血糖素治疗效果的肌肉特异性数据。

The authors conclude that the introduction of objective and comprehensive ways of assessing muscle health (including accurate and meaningful assessments of muscle quantity, composition, function, mobility, and strength) is important for the future development of GLP-1-based therapies and patient-centric treatment optimization..

作者得出结论，引入客观和全面的评估肌肉健康的方法（包括对肌肉数量，组成，功能，活动性和力量的准确和有意义的评估）对于基于GLP-1的疗法的未来发展和以患者为中心的治疗优化是重要的。。

As drug development activity increases in the obesity indication and branches out towards aiming for weight reduction with preserved muscle health, it is paramount to include measures such as the muscle volume z-score and muscle fat infiltration, in order to understand the safety and benefit of drugs achieving significant and/or rapid weight reduction.

随着药物开发活动在肥胖适应症中的增加，并转向以保持肌肉健康为目标的减肥，至关重要的是要包括肌肉体积z评分和肌肉脂肪浸润等措施，以了解药物的安全性和益处实现显着和/或快速减肥。

AMRA is committed to pioneering not only the development of powerful biomarker methodologies such as the muscle volume z-score in order to augment drug development, but also to the generation of normative data, providing context to future clinical trials and basis for interpretation of clinical benefits related to improving/maintaining muscle health.

AMRA不仅致力于开发强大的生物标志物方法，如肌肉体积z评分，以增加药物开发，而且致力于生成规范数据，为未来的临床试验提供背景，并为解释与改善/维持肌肉健康有关的临床益处奠定基础。

These initiatives will help ensure that the obesity field develops products with safety and the impact on vulnerable populations in mind..

这些举措将有助于确保肥胖领域开发安全的产品，并考虑到对弱势人群的影响。。

You can read the full article to learn more about MRI-based muscle assessment and its use in determining the relationship between drug-induced weight reduction and muscle health here.

您可以阅读整篇文章，以了解更多有关基于MRI的肌肉评估及其在确定药物减肥与肌肉健康之间关系中的用途。

Learn more about AMRA Medical and how the use of MRI-based fat distribution and muscle composition analysis is advancing disease research in metabolic diseases including obesity, and beyond.

了解有关AMRA Medical的更多信息，以及如何使用基于MRI的脂肪分布和肌肉成分分析来推进包括肥胖在内的代谢性疾病的疾病研究。

About AMRA Medical

关于AMRA Medical

AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans.

AMRA Medical是一家健康信息学和精准医学公司，开创了人体成分分析的先河，为推进临床研究和患者护理计划提供了前沿解决方案。AMRA的金标准技术提供多种脂肪和肌肉生物标志物，这些标志物仅来自快速的全身MRI扫描。

AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform..

AMRA致力于通过其创新平台提供支持服务，推动变革性护理，简化研究和临床护理环境中的重要决策。。

Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.

了解有关AMRA Medical基于MRI的解决方案的更多信息，请访问https://amramedical.com/solutions，或与我们的专家团队联系，在info@amramedical.com.

Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.

关注LinkedIn上的AMRA，了解身体成分和精准医学的最新更新。